T1	Participants 121 150	acute promyelocytic leukemia:
T2	Participants 199 233	acute promyelocytic leukemia (APL)
T3	Participants 703 884	previously untreated adult APL patients registered to protocol INT 0129 by the Eastern Cooperative Oncology Group, the Southwest Oncology Group, and the Cancer and Leukemia Group B.
T4	Participants 885 949	Of 279 clinically eligible cases, 230 were molecularly evaluable
T5	Participants 2419 2432	APL patients.
